| Literature DB >> 35305676 |
Belinda Rina Marie Spagnoletti1,2, Linda Rae Bennett3, Christina Keenan4, Suman Surendra Shetty4, Lenore Manderson5,6, Barbara McPake4, Siswanto Agus Wilopo7.
Abstract
BACKGROUND: Gynaecological cancers are among the most prevalent cancers worldwide, with profound effects on the lives of women and their families. In this critical review, we explore the impacts of these cancers on quality of life (QOL) of women in Asian countries, and highlight areas for future inquiry.Entities:
Keywords: Female cancer; Health-related quality of life; Mental health; Patient experiences; Physical health; Psychosocial support; Sexuality
Mesh:
Year: 2022 PMID: 35305676 PMCID: PMC8934499 DOI: 10.1186/s12978-022-01369-y
Source DB: PubMed Journal: Reprod Health ISSN: 1742-4755 Impact factor: 3.223
Standardised instruments and scales applied in 36 articles
| Instrument / scale name | Number of articles applied in | Applied in articles |
|---|---|---|
| European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30 Version 3 (EORTC QLQ-C30) | 11 | [ |
| Hospital Anxiety and Depression Scale (HADS) | 9 | [ |
| European Organization for Research and Treatment of Cancer Quality of Life Cervical Cancer Module 24 (EORTC QLQ‐CX24) | 5 | [ |
| Female Sexual Function Index (FSFI) | 4 | [ |
| Functional Assessment of Cancer Therapy-General Version 4 (FACT-G) | 4 | [ |
| Sexual Function—Vaginal Changes Questionnaire (SVQ) | 2 | [ |
| Medical Outcomes Study Short Form-36 (MOS SF-36) | 2 | [ |
| Mishel’s Uncertainty in Illness Scale (MUIS) | 2 | [ |
| Medical Outcomes Study Social Support Survey (MOS-SSS) | 2 | [ |
| World Health Organization Quality of Life Scale (WHOQOL-BREF) | 2 | [ |
| Psychosocial Adjustment to Illness Scale (PAIS) or PAIS Self-Report (PAIS-SR) | 2 | [ |
| Rosenberg Self-Esteem Scale (SES) | 2 | [ |
| Perceived Social Support Scale (PSSS) | 2 | [ |
| Functional Assessment of Cancer Therapy-Cervix Questionnaire (FACT-CX) | 2 | [ |
| Herth Hope Index (HHI) | 2 | [ |
| European Organization for Research and Treatment of Cancer Quality of Life Ovarian Cancer Module 28 (EORTC-QLQ-OV28) | 2 | [ |
| Sexual Activity Questionnaire (SAQ) | 1 | [ |
| Profile of Mood States (POMS) | 1 | [ |
| Positive & Negative Affect Schedule (PANAS) | 1 | [ |
| Ruminative Responses Scale (RRS) | 1 | [ |
| Emotion Regulation Questionnaire (ERQ) | 1 | [ |
| Derogatis Sexual Functioning Inventory (DSFI) | 1 | [ |
| Mastery Scale (MS) | 1 | [ |
| Brief Resilience Coping Scale (BRCS) | 1 | [ |
| Social Support Scale (SSS) | 1 | [ |
| Body Image Scale (BIS) | 1 | [ |
| Functional Assessment of Cancer Therapy—Ovary (FACT-O) | 1 | [ |
| Functional Assessment of Chronic Illness Therapy-Spiritual Well-being Scale (FACT-Sp) | 1 | [ |
| Hamilton Anxiety Scale (HAM-A) | 1 | [ |
| Perceived Stress Scale (PSS-10) | 1 | [ |
| Resilience Scale (RS) | 1 | [ |
| EuroQoL (EQ-5D-3L) | 1 | [ |
| Sexual Function After Gynaecologic Illness Scale (SFAGIS) | 1 | [ |
| Symptom Distress Scale (SDS) | 1 | [ |
| Sense of Coherence Scale 13 (SOC-13) | 1 | [ |
| Life Orientation Scale-Revised (LOT-R) | 1 | [ |
| General Self-efficacy Scale (GSES) | 1 | [ |
| National Health and Social Life Survey (NHSLS) | 1 | [ |
| McGill Quality of Life Questionnaire (MQOL) | 1 | [ |
| Interpersonal Support Evaluation List (ISEL) | 1 | [ |
| Fear of Cancer Recurrence Inventory (FCRI) | 1 | [ |
Memorial Symptom Assessment Scale-Short Form (MSAS-SF) | 1 | [ |
| Type-D Personality Scale-14 (DS14) | 1 | [ |
| M. D. Anderson Symptom Inventory (MDASI) | 1 | [ |
Fig. 1Phases in developing a narrative synthesis of QOL among women affected by gynecological cancers in Asia. Adapted from Greenhalgh and colleagues [24]
Countries in South, South East and East Asia included in initial search
| Country* | 2021 World Bank income classification | World Health Organization Member State Region | Number of articles and studies included in review |
|---|---|---|---|
| Bangladesh | LM (low middle income) | South East Asia (SEA) | |
| Bhutan | LM | SEA | |
| Brunei Darussalam | HIGH (high income) | Western Pacific (WP) | |
| Cambodia | LM | WP | |
| Laos | LM | WP | |
| Macao | HIGH | WP | |
| Malaysia | UM | WP | |
| Maldives | UM | SEA | |
| Mongolia | LM | WP | |
| Myanmar | LM | SEA | |
| Nepal | LM | SEA | |
| North Korea | LOW (low income) | SEA | |
| Philippines | LM | WP | |
| Sri Lanka | LM | SEA | |
| Timor-Leste | LM | SEA | |
| Vietnam | LM | WP |
*Countries from which studies were included in this review are given in italics
Search strategy
| “reproductive cancer” OR “gyn*ecolog* cancer” or “women* cancer” OR “cervical cancer” or “fallopian tube cancer” OR “ovarian cancer” OR “vulvar cancer” OR “vaginal cancer” OR “endometrial cancer” OR “uterine cancer” OR “HPV” OR “human papillomavirus” | |
| AND | “quality of life” OR “QOL” OR “women* experience*” OR “patient experience*” OR “survivor*” |
| AND | “Asia” OR “Southeast Asia” OR “South Asia” OR “East Asia” OR “Bangladesh” OR “Bhutan” OR “Democratic People’s Republic of Korea” OR “North Korea” OR “India” OR “Indonesia” OR “Maldives” OR “Myanmar” OR “Burma” OR “Nepal” OR “Sri Lanka” OR “Thailand” OR “Timor-Leste” OR “East Timor” OR “Taiwan” OR “China” OR “Philippines” OR “Republic of Korea” OR “South Korea” OR “Cambodia” OR “Lao People’s Democratic Republic” OR “Laos” OR “Viet Nam” OR “Vietnam” OR “Japan” OR “Malaysia” “Mongolia” OR “Singapore” OR “Brunei Darussalam” OR “Brunei” OR “Hong Kong” OR “Macao” |
| NOT | “cellular biology” OR “molecular biology” OR “neoplasm” |
Fig. 2Literature search on quality of life among women affected by gynecological cancer in Asian countries (PRISMA flow diagram)
| Authors | Date | Country | Cancer types | Participant status | Study type | N = | Standardised instruments utilised |
|---|---|---|---|---|---|---|---|
| Ratanasiri et al. [ | 2000 | Thailand | CC | During treat; post-treat | Mixed | 208 (208 in quant part & 79 in qual) | N/A |
| Molassiotis et al. [ | 2000 | Hong Kong | OC, CC, UC (EC) | Post-treat | Mixed | 62 (62 in quant part, 19 in qual) | WHOQOL-BREF; POMS; PAIS |
| Chan et al. [ | 2001 | Hong Kong | OC, UC, CC, GTD | Post-treat | Quant | 53 | HAM-A |
| Molassiotis et al. [ | 2002 | Hong Kong | OC, CC, UC (EC) | Post-treat | Qual | 18 | – |
| H Zhao et al. [ | 2003 | China | OC, GTD, OTHER | Post-treat | Quant | 216 (191 patients & 25 nurses) | QLQ-C30 |
| CWH Chan et al. [ | 2001 | Hong Kong | CC, OC, UC (EC & CORPUS) | Post-treat | Qual | 18 | – |
| Kritcharoen et al. [ | 2005 | Thailand | CC | Post-treat | Mixed | 194 (97 couples in quant part & 12 (6 couples) in qual) | N/A |
| Somjai & Chaipoom [ | 2006 | Thailand | CC, OC & UNKNOWN | Post-diagnosis | Mixed | 90 | N/A |
| So & Chui [ | 2007 | Hong Kong | CC | Post-treat | Qual | 8 | – |
| Park et al. [ | 2007 | Korea | CC | Post-treat | Quant | 860 | QLQ-C30 QLQ-CX24 NHSLS |
| Tangjitgamol et al. [ | 2007 | Thailand | CC | Post-treat | Mixed | 105 | N/A |
| Ding et al. [ | 2007 | China | OC | During treat | Quant | 61 | FACT-O PSSS |
| Lai et al. [ | 2009 | Hong Kong | CC | Post-diagnosis; Post-treat | Quant | 173 | WHOQOL-BREF |
| Kobayashi et al. [ | 2009 | Japan | CC | Post-treat | Quant | 60 | HADS; FACT-G; SES |
| Hsu et al. [ | 2009 | Taiwan | “UTERINE CERVICAL CANCER” | Post-treat | Quant | 202 | QLQ-C30 |
| Kim et al. [ | 2010 | Korea | CC | Post-treat | Quant | 828 | HADS; QLQ-C30; QLQ-CX24; MQOL |
| Tang et al. [ | 2010 | Hong Kong | CC, UC, OC, MIXED | Post-treat | Quant | 134 | DSFI; MS; SSS; BRCS |
| Suzuki et al. [ | 2011 | Japan | CC, EC, OC & OTHER | Post-diagnosis | Quant | 214 | HADS |
| Oshima et al. [ | 2011 | Japan | CC, UC (EC), OC, VUC | Post-treat | Qual | 28 | – |
| Song et al. [ | 2012 | Korea | CC | Post-treat | Quant | 81 | FSFI |
| Zeng et al. [ | 2012 | China | CC, OC, UC, VUC | Post-treat | Quant | 156 | N/A |
| Xie et al. [ | 2013 | China | CC | Post-diagnosis | Quant | 194 | MOS-SF-36 |
| Ding et al. [ | 2013 | China | CC | Post-diagnosis | Quant | 106 | FACT-CX; SOC-13 |
| Li et al. [ | 2013 | China | CC | Post-treat | Quant | 2,268 | QLQ-C30; QLQ-CX24; SAQ |
| Oshima et al. [ | 2013 | Japan | CC, UC (EC), OC, VUC | Post-treat | Qual | 28 | – |
| ZM Zhao et al. [ | 2014 | China | CC | Post-diagnosis; Post-treat | Quant | 194 | EQ-5D |
| Yang et al. [ | 2014 | China | CC | Post-diagnosis | Quant | 224 | HADS; HHI; LOT-R; GSES |
| Chow et al. [ | 2014 | Hong Kong | CC, UC, OC | Post-diagnosis | Mixed | 26 | SVQ; FACT-G MUIS HADS MOS-SSS |
| Ding et al. [ | 2015 | China | CC | Post-diagnosis | Qual | 14 | – |
| Li et al. [ | 2015 | Taiwan | CC | Post-treat | Quant | 110 | QLQ-C30; SES; MOS-SSS |
| Lee et al. [ | 2015 | Taiwan | CC, OC, UC (EC) | Post-treat | Qual | 11 | – |
| Shao et al. [ | 2016 | China | CC | Post-treat | Quant | 95 | PANAS; RRS; ERQ |
| W Zhou et al. [ | 2016 | China | CC | Post-treat | Quant | 140 | FACT-CX; FACT-Sp; FSFI |
| Afiyanti et al. [ | 2016 | Indonesia | CC | Post-treat | Quant | 106 (53 couples) | FSFI |
| L Zhou et al. [ | 2017 | China | CC | Post-treat | Quant | 173 | |
| Daga et al. [ | 2017 | India | CC | Post-treat | Quant | 48 | FSFI |
| Li et al. [ | 2017 | Taiwan | CC | Post-treat | Quant | 290 | QLQ-C30; QLQ-CX24 |
| Tsai et al. [ | 2017 | Taiwan | CC, UC (EC), OC | Post-treat | Qual | 23 | – |
| Wu et al. [ | 2017 | Taiwan | GC (UC, CC, OC & “other”) | Post-diagnosis | Quant | 167 | QLQ-C30; SDS |
| Liu et al. [ | 2017 | China | OC | During treat | Quant | 198 | HADS; PSS-10; HHI; RS |
| Wen et al. [ | 2017 | China | OC | During treat | Quant | 95 | PSSS; HADS; QLQ-OV28; QLQ-C30; |
| Shao et al. [ | 2017 | China | OC | During treat | Quant | 95 | QLQ-C30; QLQ-OV28 |
| Hsu et al. [ | 2017 | Taiwan | OC, CC, VAC, US, EC | During treat | Quant | 89 | N/A |
| Thapa et al. [ | 2018 | China | CC | Post-treat | Quant | 256 | QLQ-C30; QLQ-CX24 |
| Chow et al. [ | 2018 | Hong Kong | CC, UC, OC, OTHERS (NOT SPECIFIED) | Post-treat | Quant | 225 | SFAGIS; MOS-SF-36; PAIS-SR |
| Teo et al. [ | 2018 | Singapore | GC | Post-treat | Quant | 104 | FACT-G; BIS |
| Hu et al. [ | 2018 | China | GC | Post-diagnosis | Quant | 394 | HADS |
| Wijayanti et al. [ | 2018 | Indonesia | GC (NOT SPECIFIED) | Post-treat | Quant | 153 | FCRI; ISEL |
| Kim et al. [ | 2018 | Korea | OC | During treat | Quant | 150 | DS14; MSAS-SF; FACT-G |
| Chen et al. [ | 2019 | China | GC (types not specified) | Post-treat | Quant | 1192 | N/A |
| Tsao & Creedy [ | 2019 | Taiwan | OC | During treat | Quant | 60 | MDASI |
| Afiyanti et al. [ | 2020 | Indonesia | CC | Post-treat | Qual | 32 (16 couples) | – |
| Chow et al. [ | 2020 | Hong Kong | UC, OC, CC | Post-diagnosis | Quant | 191 | HADS; MUIS; SVQ; |
Cancer types—CC cervical cancer, OC ovarian cancer, UC uterine cancer, GTD gestational trophoblastic disease, EC endometrial cancer, CORPUS cancer of the corpus, VUC vulva cancer, US uterine sarcoma, VAC vaginal cancer; participant status—During treat participants were undergoing primary, neoadjuvant or adjuvant therapy for gynecological cancer; Post-diagnosis participants had been diagnosed with gynecological cancer, but had not commenced therapy; Post-treat participants primary, neoadjuvant or adjuvant therapy for gynecological cancer had concluded; Study type—Mixed mixed methods research; Qual qualitative research; Quant= quantitative research